TIMI (Thrombolytics and Myocardial Infarction Study) Troponin-I data guide interventionists:
This article was originally published in Clinica
Executive Summary
Heart attack patients with raised troponin-I should be treated more aggressively, according to data from the TIMI-IIIB trial (Thrombolytics and Myocardial Infarction Study). Patients with elevated levels had a significantly better outcome if they underwent early intervention rather than a conservative strategy of catheterisation followed by intervention, said Dr Elliot Antman of the Brigham & Women's Hospital during a presentation at the American Heart Association's annual meeting (Anaheim, California). For every ng/ml that troponin-I increased, mortality rose 10%.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.